TABLE 3.

Late effects^a of treatment with MB-III and liposomal amphotericin B on acute and established L. donovani infections in hamsters

Treatment groupb	Body wt (g) on day 0c	% Body wt gain at day 56c	Survival		Liver wt and burdensd			Other target organsd
			No. of survivors at necropsy	Day post- infectionc	Wt (mg)c	LDUc	% Reduc- tion	Spleen wt (mg)c	No. of animals with positive:
									Spleen	Bone marrow
Treatment of acute infection on day 1 postinfection
Control (no treatment)	188 ± 38	−69 ± 6	2	53 ± 5	8,056 ± 1,382	100,147 ± 58,715		828 ± 66	2	2
MB-III at 0.2 mg/kg s.c.	161 ± 16	−52 ± 17	2	54 ± 3	7,082 ± 2,642	17,012 ± 21,508	83.0	1,477 ± 1,160	2	2
MB-III at 0.4 mg/kg s.c.	200 ± 12	−8 ± 7	3	51 ± 7	10,614 ± 2,663	172 ± 297	99.8	2,007 ± 1,563	3	3
MB-III at 0.8 mg/kg s.c.	176 ± 30	6 ± 9	4	54 ± 5	9,608 ± 2543	0 ± 0	100	666 ± 195	4	0
Amphotericin Be at 5 mg/kg i.v.f	163 ± 29	17 ± 8	5	56 ± 0	9,317 ± 1302	0 ± 0	100	629 ± 456	4	2
Treatment of chronic infection on day 28 postinfection
Control (no treatment)	142 ± 18	NAg	0	50 ± 7	NDh	ND		ND	ND	ND
MB-III at 0.2 mg/kg s.c.	157 ± 30	NA	0	48 ± 12	ND	ND	ND	ND	ND	ND
MB-III at 0.4 mg/kg s.c.	146 ± 23	NA	0	68 ± 14	ND	ND	ND	ND	ND	ND
MB-III at 0.8 mg/kg s.c.	158 ± 39	−36 ± 13	3	78 ± 9	10,067 ± 1,972	5 ± 6	ND	475 ± 181	0	0
Amphotericin B at 5 mg/kg i.v.f	173 ± 35	−38 ± 26	3	81 ± 4	34,901 ± 39,093	1,347 ± 2,298	ND	572 ± 224	0	0

^aEarly effects of treatment were determined by necropsy at day 56 posttreatment.

^bGroups of five animals each (males and females) received a single dose.

^cValues are means ± standard deviations.

^dOnly survivers were evaluated.

^eLiposomal amphotericin B (AmBisome).

^fi.v., intravenously.

^gNA, not applicable.

^hND, not done.